Genentech/OSI Tarceva Shows Two-Month Survival Improvement Over Placebo

Genentech/OSI's anti-EGFR agent Tarceva is associated with a two-month improvement in survival for refractory non-small cell lung cancer patients, according to pivotal trial data presented at the American Society of Clinical Oncology annual meeting in New Orleans June 7